Evidence map›Paper›PMID 22910038›Full record

ArticleBioorganic & medicinal chemistry letters2012

Phenolic compounds as antiangiogenic CMG2 inhibitors from Costa Rican endophytic fungi.

Shugeng Cao, Lorna Cryan, Kaiane A Habeshian, Catalina Murillo, Giselle Tamayo-Castillo, Michael S Rogers, Jon Clardy

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Shugeng CaoDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA.
Lorna Cryan
Kaiane A Habeshian
Catalina Murillo
Giselle Tamayo-Castillo
Michael S Rogers
Jon Clardy
Boston Children's Hospital · USHarvard University · USNational Biodiversity Institute · CRUniversidad de Costa Rica · CR

Funding

Treatments for Nipah Virus InfectionU54AI057159 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KASPER, DENNIS L. · 2003 to 2013
$113.7M
of Natural Product based Drugs and Bioenergetic Materials from Costa Rican BiotaU01TW007404 · FIC · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHERMAN, DAVID H · 2005 to 2013
$7.6M
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin ReceptorsR01EY018829 · NEI · BOSTON CHILDREN'S HOSPITAL · PI ROGERS, MICHAEL SEAN · 2008 to 2012
$2.0M
FIC NIH HHS U01 TW007404NEI NIH HHS R01 EY018829NIAID NIH HHS U54 AI057159
6 · The paper itself

Abstract

Targeting and inhibiting CMG2 (Capillary Morphogenesis Gene protein 2) represents a new strategy for therapeutic agents for cancer and retinal diseases due to CMG2's role in blood vessel growth (angiogenesis). A high throughput FRET (Förster Resonance Energy Transfer) assay was developed for the identification of CMG2 inhibitors as anti-angiogenetic agents. Bioassay-guided separation led to the isolation and identification of two new compounds (1 and 2) from CR252M, an endophytic fungus Coccomyces proteae collected from a Costa Rican rainforest, and one known compound (3) from CR1207B (Aurapex penicillata). Secondary in vitro assays indicated anti-angiogenic activity. Compound 3 inhibited the endothelial cell migration at 52 μM, but did not show any endothelial cell antiproliferative effect at 156 μM. The structure of the two new compounds, A (1) and B (2), were elucidated on the basis of extensive spectroscopic analysis, including 1D and 2D NMR experiments.

Indexed as

AscomycotaCell MovementCell ProliferationCosta RicaDose-Response Relationship, DrugEndothelial CellsHumansMembrane ProteinsMolecular StructurePhenolsReceptors, PeptideStereoisomerismStructure-Activity RelationshipANTXR2 protein, humanMembrane ProteinsPhenolsReceptors, Peptide

Identifiers

PMID22910038
PMCPMC3563091
OpenAlexW2082413572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.